A. Oliver Sartor, MD, presented “New Concepts in Molecularly Targeted Radiation in Prostate Cancer” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Sartor, A. Oliver. “New Concepts in Molecularly Targeted Radiation in Prostate Cancer.” February 9, 2025. Accessed Nov 2025. https://grandroundsinurology.com/new-concepts-in-molecularly-targeted-radiation-in-prostate-cancer/
New Concepts in Molecularly Targeted Radiation in Prostate Cancer – Summary
A. Oliver Sartor, MD, Mayo Clinic, Rochester, Minnesota, discusses innovative approaches in molecularly targeted radiation for prostate cancer. In this 13-minute presentation, Dr. Sartor outlines the concept of theranostics, which combines imaging and therapy using radiopharmaceuticals to detect and treat prostate cancer.
Dr. Sartor highlights PSMA as a proven target and the use of Lutetium-177 for treating PSMA-positive metastatic castration-resistant prostate cancer. He introduces key clinical trials, such as PSMAfore, SPLASH, and ECLIPSE, which evaluate Lutetium-177 in earlier treatment stages. He also discusses the PSMAddition trial, which explores its role in metastatic castration-sensitive prostate cancer.
Sartor highlights promising strategies combining radiopharmaceuticals with DNA repair inhibitors like PARP inhibitors and emerging data on alpha emitters like Actinium-225 for enhanced tumor control. He stresses the potential for combining isotopes with immunotherapy and other agents to improve outcomes. Dr. Sartor emphasizes the need to expand molecular radiation therapy to additional cancer types and highlights future directions for more precise, targeted, and effective treatment strategies.
About the 35th International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.
ABOUT THE AUTHOR
Dr. Sartor earned his MD from Tulane University School of Medicine in 1982. After training at the University of Pennsylvania and Tulane Medical School, he completed a fellowship at the National Cancer Institute, where he focused on advanced prostate cancer therapies. He held positions at LSU Medical School and LSU Health Sciences Center, directing oncology programs before joining Dana Farber Cancer Institute in 2006. In 2008, he returned to Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research.
An internationally recognized expert in prostate cancer, Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.
Having published over 500 scholarly articles and having served as the past Chairman of the Department of Defense Prostate Integration Panel, Dr. Sartor, in addition to being the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology, is the Medical Oncology Chair of the GU Committee of the NRG, the Assistant Dean for Oncology at Tulane University School of Medicine, the Medical Director of the Tulane Cancer Center, and the Editor-in-Chief of the peer-reviewed journal, Clinical Genitourinary Cancer. In addition, he is currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).
